In 1976, a Congolese virologist, Jean-Jacques Muyembe-Tamfum, traveled to the village of Yambuku to investigate a mysterious illness killing patients and health workers alike. He collected blood samples with his bare hands; sent to Belgium, they were identified as the Ebola virus. Honored and recognized by Time Magazine, Nature, and the Royal Society as one of the most consequential virologists of the last century, he went on to develop one of the first effective Ebola treatments.

We have always had talent like Prof. Muyembe. African expertise is robust and growing. And yet, Africa carries a quarter of the world’s disease burden but produces less than 2 percent of its own medicines. What we have lacked is the manufacturing base, the regulatory architecture, and the procurement frameworks to turn that talent into medicines Africa can make, own, and sustain.

Decades of financing and procurement, largely shaped elsewhere, however well-intentioned, left domestic production without the conditions it needed to grow. Decisions that uphold these structures have rarely been made in Africa. I have sat in the same rooms and had conversations about the same topics for years: Local manufacturing. Country ownership. External dependency. Sometimes it feels like déjà vu. And sometimes it makes me sad, because we have known how to solve this problem for far too long.

For many years, vaccines reaching African countries were procured through UNICEF and drugs for HIV, tuberculosis, and malaria were funded through PEPFAR and the Global Fund. These systems delivered lifesaving products, but they never fully met our needs. However, because costs were absorbed externally, the gap in production remained invisible. Then COVID-19 came. Countries with production capacity were the first to access vaccines and treatments. Africa was last. Mpox repeated the same pattern. In May 2026, the Bundibugyo strain of Ebola, with no approved vaccine or treatment, swept through the Democratic Republic of the Congo and Uganda.

The question is no longer whether Africa can manufacture, but what will finally make it happen. The following four steps are a good place to start:

First, political commitment at the continental level must translate into operational decisions. The African Union’s African Medicines Agency has entered a new phase to advance regulatory harmonization, safety and quality of health products, and coordinated market authorization across the continent under its first director general. Regulatory harmonization remains the central barrier to unlocking the capacity that already exists on this continent. Without it, factories sit idle, talent goes unused, and intent remains exactly that.

Second, the hub model must be taken seriously. Manufacturing vaccines in every country is neither viable nor sustainable. Senegal anchors West Africa: The Institute Pasteur de Dakar, which has produced yellow fever vaccines for nearly a century, recently inaugurated MADIBA, a project that created the infrastructure to produce 300 million vaccine doses annually. It is now serving as the West Africa anchor in Africa CDC’s continental manufacturing network.

Kenya, where President William Ruto serves as the African Union champion for local manufacturing, brings an existing base of more than 30 manufacturers, leads pharmaceutical exports across the Common Market for Eastern and Southern Africa (COMESA) region, and has committed to becoming the East Africa hub. South Africa, whose pharmaceutical sector is advanced, with an established manufacturing base, the World Health Organization mRNA technology transfer hub, and a regulatory authority now aligned to global standards, anchors the south. Ghana and Rwanda represent the next generation of emerging capacity.